[go: up one dir, main page]

CR9181A - Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa - Google Patents

Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa

Info

Publication number
CR9181A
CR9181A CR9181A CR9181A CR9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A
Authority
CR
Costa Rica
Prior art keywords
therapy
failed
antiangiogenesis
patients
self
Prior art date
Application number
CR9181A
Other languages
English (en)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR9181A publication Critical patent/CR9181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud describe la terapia con antagonistas de angiogenesis tales como anticuerpos antiVEGF. En particular, la solicitud describe el uso de tales antagonistas para tratar la enfermedad autoinmune en un paciente en quien ha fallado el tratamiento anterior tal como el tratamiento con DMARDs o inhibidores-TNFx.
CR9181A 2004-12-17 2007-06-13 Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa CR9181A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
CR9181A true CR9181A (es) 2008-07-31

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9181A CR9181A (es) 2004-12-17 2007-06-13 Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa

Country Status (23)

Country Link
US (2) US20060134111A1 (es)
EP (1) EP1824885A1 (es)
JP (1) JP2008524241A (es)
KR (1) KR20070086218A (es)
CN (1) CN101120020A (es)
AR (1) AR052056A1 (es)
AU (1) AU2005316403A1 (es)
BR (1) BRPI0518105A (es)
CA (1) CA2587932A1 (es)
CR (1) CR9181A (es)
IL (1) IL183347A0 (es)
MA (1) MA29366B1 (es)
MX (1) MX2007007165A (es)
NO (1) NO20073651L (es)
NZ (1) NZ555286A (es)
PE (1) PE20061075A1 (es)
RU (1) RU2007126970A (es)
SG (1) SG158089A1 (es)
SV (1) SV2006002342A (es)
TN (1) TNSN07191A1 (es)
TW (1) TW200634026A (es)
WO (1) WO2006066086A1 (es)
ZA (1) ZA200704898B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
ES2407859T3 (es) 2004-09-13 2013-06-14 Genzyme Corporation Construcciones multiméricas.
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
HUE034832T2 (hu) * 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010072348A1 (en) * 2008-12-23 2010-07-01 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
ES2652508T3 (es) 2010-08-06 2018-02-02 Genzyme Corporation Composiciones de antagonistas de VEGF y sus usos
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2015241038A1 (en) * 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
DK3056216T3 (en) * 2015-02-11 2017-05-08 Deutsches Krebsforsch Cancer treatment with parvovirus combined with bevacizumab
MX2020009394A (es) 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
CA3236006A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
SV2006002342A (es) 2006-06-01
MA29366B1 (fr) 2008-04-01
TNSN07191A1 (en) 2008-11-21
IL183347A0 (en) 2007-09-20
MX2007007165A (es) 2007-08-14
WO2006066086A1 (en) 2006-06-22
PE20061075A1 (es) 2006-11-15
AR052056A1 (es) 2007-02-28
CN101120020A (zh) 2008-02-06
NZ555286A (en) 2010-04-30
US20060134111A1 (en) 2006-06-22
RU2007126970A (ru) 2009-01-27
US20080214789A1 (en) 2008-09-04
ZA200704898B (en) 2009-03-25
JP2008524241A (ja) 2008-07-10
EP1824885A1 (en) 2007-08-29
KR20070086218A (ko) 2007-08-27
TW200634026A (en) 2006-10-01
SG158089A1 (en) 2010-01-29
CA2587932A1 (en) 2006-06-22
BRPI0518105A (pt) 2008-11-04
NO20073651L (no) 2007-09-10
AU2005316403A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
AR077896A1 (es) Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer.
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
EA200802204A1 (ru) Применение ингибиторов dpp iv
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ603319A (en) Diabetes therapy
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
TW200640488A (en) Extending time to disease progression or survival in cancer patients
AR062522A1 (es) Tratamiento de desordenes en cartilagos
WO2007136518A3 (en) Treatment of autoimmune disorders
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
BRPI0418157A (pt) terapêutica de tumores alogênicos
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
AR081925A1 (es) Uso de ranolazina para el tratamiento de la hipertension pulmonar
ECSP077843A (es) Tratamiento o prevención del prurito
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
UA113183C2 (xx) Спосіб лікування адикції
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
DE602006019759D1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
HK1110080A (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
DOP2005000257A (es) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)